<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

M&A deals and the pharmaceutical sector: Are your ...

2018 has so far been a productive year for M&A deals in the pharmaceutical ...

Read More

Artios Pharma’s £65m Series B to spur development ...

Key findings:

Read More

Have your say on life sciences investment trends

LSX, formerly Biotech and Money, is conducting the 3rd Investor Perception ...

Read More

Dyadic International: Working to change the game i...

Key learnings:

Read More

What life sciences companies need to know about pr...

Pre-approval access is evolving at a rapid pace. Mark Corbett (pictured), E...

Read More

Forendo Pharma receives €4m boost to progress wome...

Key learnings: Vesalius BioCapital III Partners invested €4 million in Finl...

Read More

Evox Therapeutics raises £35.5m Series B to advanc...

Key learnings: UK biotech Evox Therapeutics recently announced its £35.5 mi...

Read More

Addressing the challenges of ownership structures ...

The development of new products in the life science industry is a very time...

Read More

Exploring life sciences investment trends with Min...

Key learnings: Leading US life sciences law firm Mintz has been active in t...

Read More

Commercialise and partner successfully in Europe a...

Understand how to commercialise via partnering in Europe and other markets ...

Read More

Key challenges to scaling up early-stage investmen...

Access to venture capital and effective fundraising tactics are key to buil...

Read More

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More

Add Your Response